Results 121 to 130 of about 29,080 (157)

UPLC-Q-Exactive MS-based metabolomics integrated with species distribution modeling and AI-driven target prediction: Identifying geographical markers and functional mechanisms of <i>Chaenomeles speciosa</i> fruits. [PDF]

Food Chem X
Yuan Z, Huang L, Zheng J, Yang J, Jiang Y, Liu S, Zhang W, Liu D, Liu Y, Ge Y.   +9 more
europepmc   +1 more source

Malformation Pattern and Molecular Findings in the <i>FGFR1</i>-Related Hartsfield Syndrome Phenotype. [PDF]

Med Sci (Basel)
Gaudioso F, Pascolini G.
europepmc   +1 more source

Olverembatinib for 8p11 myeloproliferative syndrome with a positive BCR-FGFR1 fusion gene: a case report. [PDF]

Ann Hematol
Wu M, Huang L, Yao Y, Xu Y, Yang Y, Luo J, Liu Z.   +6 more
europepmc   +1 more source

Pleiotropic genes linking congenital hypogonadotropic hypogonadism and cleft lip/palate: evidence from a genomic CHH cohort study. [PDF]

Eur J Hum Genet
Correa FA, Habibi I, Zhai J, Adamo M, Wang Y, Boizot A, Zouaghi Y, Rauch A, Pekic S, Quinton R, Bonomi M, Cangiano B, Dhillo WS, Fluck CE, Nemeth A, Bouloux PM, Ferrara JM, Pignatelli D, Halász Z, Perdices-Lopez C, Messina A, Niederländer NJ, Santoni F, Acierno JS, Pitteloud N.   +24 more
europepmc   +1 more source

Identification of small molecule inhibitors targeting FGFR through molecular docking-based screening. [PDF]

Front Oncol
Hou W, Liu K, Wang P, Zheng K, Kong Q, Wang X, Zhao Q, Cheng L.   +7 more
europepmc   +1 more source

Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps. [PDF]

Drug Des Devel Ther
Erul E, Cifuentes-Canaval S, Santhosh A, Sokolović E, Della Mura M, Cazzato G, Kubilay Tolunay P, Rizzo A.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer

Applied Immunohistochemistry & Molecular Morphology, 2022
Clinical trials in patients with ER+ breast cancer with or without FGFR pathway somatic alterations have shown limited clinical benefit from treatment with FGFR tyrosine kinase inhibitors alone or in combination with endocrine therapy. This is likely because of an inadequate predictive biomarker to select appropriate patients.
Gonzalez-Ericsson, Paula I, Servetto, Alberto, Formisano, Luigi, Sánchez, Violeta, Mayer, Ingrid A, Arteaga, Carlos L, Sanders, Melinda E   +6 more
openaire   +3 more sources

FGFR1 and FGFR2 Mutations in Pfeiffer Syndrome

Journal of Craniofacial Surgery, 2013
Pfeiffer syndrome (PS) (MIM 101600) is one of the most common syndromic forms of craniosynostosis. It is characterized by craniosysnostosis, midface hypoplasia, broad and medially deviated thumbs, and great toes with partial syndactyly of the digits. Here, we described clinical and genetic features of 12 unrelated Thai individuals with PS.
Chayanin, Chokdeemboon, Charan, Mahatumarat, Nond, Rojvachiranonda, Siraprapa, Tongkobpetch, Kanya, Suphapeetiporn, Vorasuk, Shotelersuk   +5 more
openaire   +2 more sources

Abstract A20: FGFR1-amplified squamous cell lung cancers depend on FGFR1

Clinical Cancer Research, 2010
Abstract In lung adenocarcinomas of never-smokers EGFR mutations or EML4-ALK gene fusions are frequent genomic events that both expose prime therapeutic targets. By contrast, squamous cell lung cancer (SQLC) is almost invariably associated with smoking; in this subgroup of patients, no attractive therapeutic target has so far been ...
Martin L. Sos, Roman K. Thomas
openaire   +1 more source